State of Tennessee Department of Treasury Increases Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

State of Tennessee Department of Treasury boosted its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 25.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 105,482 shares of the biotechnology company's stock after buying an additional 21,367 shares during the quarter. State of Tennessee Department of Treasury's holdings in ADMA Biologics were worth $1,809,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in shares of ADMA Biologics by 106.6% in the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 967 shares during the last quarter. Mark Sheptoff Financial Planning LLC purchased a new stake in shares of ADMA Biologics during the fourth quarter worth $35,000. Vision Financial Markets LLC acquired a new position in ADMA Biologics during the fourth quarter worth about $51,000. AlphaQuest LLC acquired a new stake in ADMA Biologics in the 4th quarter valued at about $84,000. Finally, CIBC Private Wealth Group LLC boosted its stake in ADMA Biologics by 137.1% during the fourth quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock worth $95,000 after buying an additional 2,954 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Up 1.1 %

ADMA traded up $0.25 during trading hours on Friday, hitting $23.52. 2,106,251 shares of the company's stock were exchanged, compared to its average volume of 3,689,562. The firm has a market cap of $5.59 billion, a P/E ratio of 84.00 and a beta of 0.57. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 12-month low of $6.65 and a 12-month high of $25.67. The firm has a 50 day moving average of $19.60 and a 200 day moving average of $18.50.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.